Core Insights - Recursion has established a strong leadership position in the drug discovery space by leveraging AI/ML solutions and enhancing its technological and operational capabilities over the past decade [1][11] - The company is set to provide updated pipeline guidance during its Download Day event on June 24, 2024, aimed at investors and stakeholders [13] Pipeline Updates - Seven clinical trial readouts are anticipated within approximately 18 months, including: - REC-994 for Cerebral Cavernous Malformation with topline Phase 2 data readout in September 2024 - REC-2282 for Neurofibromatosis Type 2 with preliminary Phase 2 data readout in Q4 2024 - REC-4881 for Familial Adenomatous Polyposis with preliminary Phase 2 data readout in H1 2025 - REC-3964 for Clostridioides difficile Infection with Phase 2 study initiation in Q4 2024 and preliminary data readout by the end of 2025 [8] Partnership Developments - Recursion has delivered multiple data packages to Bayer and initiated its first joint oncology project, which is expected to advance rapidly towards Lead Series nomination [7][15] - Bayer will be the first external beta-user of Recursion's LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development, enhancing the research environment for both companies [7][15] Technological Advancements - The company has achieved significant milestones in its platform, including: - Potential to achieve an estimated 90 times the lab throughput compared to manual approaches [4] - Development of a genome-scale transcriptomics knockout map and multimodal mapping, which has shown a 90% success rate in predicting compounds that failed later disease-relevant assays [4][11] Company Overview - Recursion is a leading clinical stage TechBio company focused on decoding biology to industrialize drug discovery, utilizing a platform that integrates diverse technologies and one of the world's largest proprietary biological, chemical, and patient-centric datasets [11][14]

To address this issue, companies like Recursion are trying to identify failures early on and accelerate pre-clinical development of high potential drug candidates. While there is likely significant value just in improving the productivity of pre-clinical research, late-stage clinical failures are the primary driver of costs in today's pharmaceutical R&D model, making improving clinical success rates critical to improving the return on R&D spend. Recursion believes that the development and convergence of a r ...

Investing in growth stocks can lead to significant returns for investors in the long run. But oftentimes, the best returns come from smaller stocks, which have modest market values. These stocks can be risky options, but due to their low valuations, they tend to have the most room to rise higher if their businesses prove to be the real deal. Recursion hopes that it can help develop its own pipeline with cutting-edge technology while also helping other companies. While there isn't anything significant to sho ...

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Jefferies Healthcare Conference - June 5-6, 2024 45th Annual Goldman Sachs Healthcare Conference - June 10-13, 2024 Morgan Stanley 3rd Annual Life Sciences AI Summit - June 26-27, 2024 About Recursion Recursion is a clinical stage TechBio company leading the space by decod ...

SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches. Investor Contact This proximity bias, discoverable through Recursion's proprietary biological dataset, could have many down ...

SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches. "Over several years, Recursion has built both unique scale and experience of working with CRISPR-Cas9. By combining the mas ...

Company Leadership Update - Robert Hershberg, MD, PhD, has been appointed as the new Chair of the Board of Recursion, effective at the end of the current term, replacing Martin Chavez who is stepping down after more than four years of leadership [1] - Dr Hershberg brings extensive experience in drug discovery and commercialization, having served on Recursion's Board since May 2020 and holding leadership roles at HilleVax, Celgene, and VentiRx Pharmaceuticals [2] - Chris Gibson, CEO and Co-founder of Recursion, expressed excitement about Dr Hershberg's appointment and gratitude for Martin Chavez's contributions to the company's growth [3] Company Overview - Recursion is a clinical-stage TechBio company that decodes biology to industrialize drug discovery, leveraging its proprietary Recursion OS platform and one of the world's largest biological and chemical datasets [4] - The company conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers in the world, combining technology, biology, and chemistry to advance medicine [4] - Recursion is headquartered in Salt Lake City and has offices in Toronto, Montréal, and the San Francisco Bay Area [5] Industry Impact - Recursion is positioned as a leader in the TechBio space, which is expected to revolutionize the biopharma industry through the intersection of scientific rigor and technology [3] - The company's approach to drug discovery, unconstrained by human bias and enabled by machine learning, represents the future of the industry [2]

SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of Recursion, effective at the end of this term, as Martin Chavez exits after more than four years of leadership. "I'm excited to bring my clinical and scientific expertise to support Recursion's growth as Chair of the Board," said Dr. Hershberg. "I ...

These stocks are very promising, but it's important to consider the downside, too. Things aren't so bad for investors right now. We are in a bull market even though the economy is still having some problems. However, this bull run won't last forever. There will be a slowdown, equities will fall, and many won't deliver anything approaching decent returns for years after. So it's important to find stocks that can beat the market (hopefully by a large margin) over the long run. That's not easy to do, but here ...

Recursion Pharmaceuticals (RXRX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this biotechnology company have returned +17.9%, compared to the Zacks S&P 500 composite's +6.1% change. During this period, the Zacks Medical - Drugs industry, which Recursion Pharmaceuticals falls in, has gained 7.1%. The key question now is: What could be the stock's futu ...